Axsome Therapeutics (AXSM) Cash from Investing Activities (2015 - 2026)
Axsome Therapeutics (AXSM) posted Cash from Investing Activities of -$121000.0 for Q1 2026, down 70.42% sequentially from -$71000.0 in Q4 2025, and up 64.2% YoY from -$73690.1 in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Axsome Therapeutics has reported Cash from Investing Activities for 12 years, with the latest figure at -$121000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 64.2% year-over-year to -$121000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$263000.0 (up 48.43% YoY) and the FY2025 annual result came in at -$480000.0, down 77.78% from the prior year.
- Cash from Investing Activities eased to -$121000.0 in Q1 2026 per AXSM's latest filing, from -$71000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$7000.0 in Q4 2023 and troughed at -$53.2 million in Q2 2022.
- A 5-year average of -$3.2 million and a median of -$90000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 281941.64% in 2022, then jumped 99.75% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$181000.0 in 2022, then surged by 96.13% to -$7000.0 in 2023, then tumbled by 328.57% to -$30000.0 in 2024, then tumbled by 136.67% to -$71000.0 in 2025, then slumped by 70.42% to -$121000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$121000.0, -$71000.0, and -$58000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn | -450,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -450,000.00 |
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | -71,000.00 |
| Sep 30, 2025 | -58,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Mar 31, 2024 | -98,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Sep 30, 2023 | -371,000.00 |
| Jun 30, 2023 | -133,000.00 |
| Mar 31, 2023 | -71,000.00 |
| Dec 31, 2022 | -181,000.00 |
| Sep 30, 2022 | -66,000.00 |
| Jun 30, 2022 | -53.24 Mn |
| Mar 31, 2022 | -214,000.00 |
| Dec 31, 2021 | -451.00 |
| Sep 30, 2021 | -258,677.00 |